Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWP59B)

• Drug Name: ATI-2042 Drug Info
• Synonyms: Budiodarone

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9833332
  CAS Number: CAS 335148-45-3
  TTD Drug ID: DMWP59B

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[4]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[5]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[6]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[7]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[8]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[9]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[10]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[11]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[12]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[13]

Drug(s) Targeting Calcium channel unspecific (CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[14]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[15]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[16]
Felodipine	DMOSW35	Hypertension	BA00-BA04	Approved	[17]
Nimodipine	DMQ0RKZ	Cerebral vasospasm	BA85.Z	Approved	[18]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[19]
Isradipine	DMA5XGH	Hypertension	BA00-BA04	Approved	[19]
DIPROTEVERINE HYDROCHLORIDE	DMG8U6M	Angina pectoris	BA40	Phase 3	[20]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[21]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[22]

Drug(s) Targeting Ion channel unspecific (IC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lu-AA39959	DM34FWR	Bipolar disorder	6A60	Phase 2	[23]
AZD-2927	DM6AI9N	Atrial fibrillation	BC81.3	Phase 2	[24]
Lu-AA38466	DMGUX5Y	Neurological disorder	6B60	Discontinued in Phase 1	[25]
AZD-0902	DMS7INR	Chronic obstructive pulmonary disease	CA22	Terminated	[26]

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[19]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[19]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[27]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[19]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[28]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[19]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[19]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[29]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[19]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Agonist	[2]
Ion channel unspecific (IC)	TTM7WCE	NOUNIPROTAC	Antagonist	[3]
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Agonist	[2]
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT00389792) Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9.
• [4] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [5] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [6] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [7] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [8] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [9] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [10] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [13] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [14] Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
• [15] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [16] RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
• [17] Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
• [18] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [20] Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
• [21] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
• [22] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [23] Lundbeck: leading the way in the treatment of CNS disorders.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704).
• [25] Lundbeck is developing new and promising pharmaceuticals for the treatment of depression, anxiety and psychotic disorders and for new disease areas such as stroke and alcohol dependence. Pipeline report of Lundbeck in 2008.
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129)
• [27] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [28] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [29] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.